2(a). FDA advisory panel for ATryn BLA: Jan 2009. 2(b). FDA PDUFA date for ATryn BLA: 7-Feb-2009. Possible actions on or before this date are approval for marketing, rejection, or a request for more information. Lately, the FDA has been routinely missing its PDUFA dates, so there is no assurance the FDA will actually render a decision by 2/7/09.
3. Update on the transfer of Leo’s ex-US ATryn rights to LFB. GTC has given no guidance on when this might occur; the sooner the better because the phase-2 DIC trial is on hold pending the outcome of these negotiations.
4. One or more FoB partnerships. There are several monoclonal antibodies with FoB potential in which GTC claims to have developed founder animals. GTC claims to have spoken to prospective FoB partners and hence a deal could come at any time. However, inking an FoB deal may have to wait for the political climate to improve (#msg-32325621).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.